ClinicalTrials.gg
TerminatedNCT02974114Updated Aug 28, 2018Results posted

Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain

A Phase 4 interventional study of Paracetamol and caffeine and Paracetamol in Pain, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
119th of 137
21 · median 95
Started
2016
with 8 others
Phase 4
67 of 137
5 open now
Registered
94th of 137
by date
Lead sponsor
7 of 137
GlaxoSmithKline

Among the 137 studies testing acetaminophen in Pain, this one is the 119th largest by enrollment, is one of 9 that started in 2016, is one of 67 in phase 4, and was the 94th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

This parallel, assessor blind, placebo-controlled, stratified, randomized study will investigate the effects of everyday pain on cognition and mobility in otherwise healthy individuals.

Read the detailed description

This study consisted of 3 visits. Visit 1 (Day1, Screening), minimum (min) of 7 days and maximum (max) of 28 days gap followed by Visit 2 (Day 2, pain-state assessment), a recovery period of min of 2 days and max of 30 days followed by Visit 3 (Day 3, pain-free assessment). Participants received treatment once only on Visit 2.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Aged between 18-65 years.
  • Participant is male or female.
  • Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • Adequately completes cognition and mobility familiarisation tasks in the opinion of the investigator.
  • Good general and mental health with, in the opinion of the investigator or medically qualified designee: No and relevant abnormalities in medical history or upon physical examination; absence of any condition that might impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements; >18.5 and \<30 kg/m2
  • VISIT 1 ONLY - Has experienced a minimum of two recurrent, acute pain episodes within the past 3 months or is currently suffering from a flare up episode of recurrent, acute pain; VISIT 2 ONLY - A score ≥5 to question 6 (rated on scale 0-10) on the Brief Pain Inventory - Short Form and participants presenting with only one of the following pain types: Joint (Knee, Hip); Back; Headache; Period.

Exclusion criteria

Exclusion Criteria

  • Women who are pregnant (Visit 1), women of child bearing potential who test positive on a urine pregnancy test (Visit 1 or Visit 2), females of non-child bearing potential will not be required to complete urinary pregnancy test, females not requiring a pregnancy test will be defined as: Age ≥ 50 years with spontaneous cessation of menses for 12 or more months or age \< 55 years and spontaneous menses within the past 1 year, but currently amenorrheic.
  • Women who are currently breast-feeding.
  • In the opinion of the medical designee, participant suffers from medical condition(s) that may be aggravated due to testing procedures or may impact the interpretation or integrity of data. Conditions related to renal, hepatic, respiratory, blood, immune systems or heart dysfunction will be considered.
  • Participant is colour blind.
  • Current (within 14 days of the start of the study) or regular use of any prescription, over-the-counter (OTC), herbal medicine unless the medication has been approved by the study physician. OTC analgesics for pain relief and vitamin supplements are permitted only until 48 hours prior to study visits; Current or in the 30 days prior to dosing use of any drug, food, herbal product, or dietary supplement known to induce or inhibit hepatic drug metabolism (e.g. barbiturates, theophylline, cimetidine, or erythromycin) ;Use of analgesics and anti-inflammatory drugs 48 hours prior to dosing at Visit 2; Known to be taking any other medication which could counteract with paracetamol and/or caffeine; Current or past use of anti-depressants or psychoactive drugs within the previous 2-years.
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Positive breath alcohol test at Visit 2 and positive urine drugs of abuse test at Visit 2.
  • Participation in another clinical study (including cosmetic studies) or receipt of an product within 7 days of the screening visit or previous participation and randomization in this study.
  • Participant has excessive frequent caffeine intake equivalent to 6 cups of brewed coffee or 12 cups of tea per day; Unwilling to abstain from any caffeine products from 4 hours prior to the visit on assessment days (Visit 2 and 3); Current Smoker (or regular nicotine consumption): Participant smokes more than 3 cigarettes per day (or equivalent for e-cigarettes, chewing tobacco or pipes). Investigator will ensure there is no impact of withdrawal effect from those with nicotine dependence; Current Alcohol Consumer: Participant consumes greater than 21 units of alcohol per week (male) and 14 units per week (female) (e.g. Spirit 25ml = 1 unit / AlcoPop 275ml = 1.5 unit / Bottle of beer 330 ml = 1.7 unit / Glass of wine 175ml = 2.1 unit / Pint of beer 568 ml = 3 unit).
  • Members of the study site staff or members of their immediate family.
  • Any participant who in the opinion of the investigator should not take part in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Paracetamol and caffeine

    Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.

    Drug: Paracetamol and caffeine

  • Experimental
    Paracetamol

    Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.

    Drug: Paracetamol

  • Placebo comparator
    Placebo

    Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.

    Other: Placebo

Interventions

  • DrugParacetamol and caffeine

    Drug pages: Acetaminophen · Caffeine

    Test product containing 500 mg paracetamol and 65 mg caffeine

  • Test product containing 500 mg paracetamol

  • OtherPlacebo

    Placebo to match paracetamol 665mg sustained release tablets

06

What researchers measure

Primary outcomes

  1. Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2)

    Error adjusted SRT was one of the main outcomes of the Axon Sports Priming Application. The Axon Sports Priming Application is a computerized test performed on a tablet device that measures cognitive performance, namely psychomotor speed. Axon sports test assessment included 1. Pain-state assessment performed at Visit 2 (Day 2 pre-treatment assessment and post-treatment assessment 1hour \[hr\] ± 15 minutes \[mins\] post-dosing) and 2. Pain-free assessment performed at Visit 3 (Day 3).

    Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study

  2. Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2)

    The reaction time of five-choice reaction time task (provided by Cambridge Cognition) was measured. In five-choice reaction time task, all the participants hold down a button at the bottom of the screen till a yellow spot appears in one of the five circles at the top of the screen. Participants then released the button and touch inside of the circle where the yellow spot appeared as quickly as they can. The median duration, between the onset of the stimulus and the release of the button, was recorded as reaction time. Calculated for correct, assessed trials where the stimulus appeared in any one of five locations.

    Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study

  3. Change From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2)

    OTS was a measure of executive function and takes approximately 10 minutes to complete. The participant was shown two displays containing three coloured balls. The displays were presented in such a way that they can easily be perceived as stacks of coloured balls held in stockings or socks suspended from a beam. There was a row of numbered boxes along the bottom of the screen. The test administrator first demonstrated to the participant how to use the balls in the lower display to copy the pattern in the upper display, and completed one demonstration problem, where the solution requires one move. The participant then completed three further problems, one each of two moves, three moves, and four moves. Next, the participant was shown further problems, and participants worked out in their head how many moves the solutions to these problems required, and then touch the appropriate box at the bottom of the screen to indicate their response.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  4. Change From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2)

    AST was a measure of executive attention. The test displayed an arrow which can appear on either side of the screen and can point in either direction. Each trial displayed a cue at the top of the screen that indicates whether to press the right or left button. Some trials displayed congruent stimuli (e.g. arrow on the right side of the screen pointing to the right) whereas other trials display incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side of the screen pointing to the left). The AST congruency cost was the difference between the median latencies of response (from stimulus appearance to button press) on the trials that were congruent versus the trials that were incongruent. It was calculated by subtracting the median of congruent from incongruent latency. A positive score indicated response was faster on congruent trials and a negative score indicated response was faster on incongruent trials.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  5. Change From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2)

    SWM task was a measure of working memory. The task involved number of coloured squares (boxes) being shown on the screen. The aim of this test was to find one blue token in the boxes shown to the participants by process of elimination and used these to fill up an empty column on the right-hand side of the screen. The number of boxes gradually increased up to a maximum of eight boxes to search and the colour and position of the boxes changed from trial to trial. SWM between errors was defined as times the participant revisited a box in which a token has previously been found. This was calculated for trials of four, six and eight tokens.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  6. Change From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2)

    RVP task was measures of attention. A white box appeared in the centre of the computer screen, inside which digits, from 2 to 9, appeared in a pseudo-random order, at the rate of 100 digits per minute. Participants were requested to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register responses using the press pad. The RVPA (A prime) was the signal detection measure of sensitivity to the target, regardless of response tendency (the expected range will be 0.00 to 1.00; bad to good). RVP metric was a measure of how good the subject was at detecting target sequences.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

Secondary outcomes

  1. Change From Pain-free State (Day 3) in Grip Force in Pain State (Day 2)

    This task was a measure of grip strength. The participant held the dynamometer in their dominant hand and the arm was swung from above the head to by the side of the body. If the dominant arm or hand was painful then the non-dominant hand was used. The participant was instructed to assert maximum effort during the squeezing motion and maintain it for about 4 seconds using a metronome. Participant conducted the movement 4-times (1 practice effort and 3 test efforts) and there was a 1-minute recovery period between each effort.

    Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study

  2. Change From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2)

    Time to standing provides a simple assessment of physical mobility. From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Time to standing recorded which was measured using a stopwatch. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  3. Change From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2)

    From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort. GRF was measured during the movement analyzed using a force plate interfaced with a computer.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  4. Change From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2)

    Participants performed a walking assessment in comfortable walking shoes to measure gait parameter contact phase. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  5. Change From Pain-free State (Day 3) in Stride Length in Pain State (Day 2)

    Participants performed a walking assessment in comfortable walking shoes to measure gait parameter stride length. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

    Time frame: At Day 2 (pre and post treatment) and Day 3 of the study

  6. Change From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2)

    Participants performed a walking assessment in comfortable walking shoes to measure gait parameter walking speed over 5-10m for each foot. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

    Time frame: At Day 2 (pre and post-treatment) and Day 3

07

Results

Posted Aug 28, 2018
Limitations and caveats
The study was terminated early due to breaches of GCP guidelines observed during a GSKCH internal audit. The minimum requirement of 8 subjects per strata was not met because of early termination so some exploratory analyses were not conducted.

Participant flow

All participants were recruited at a single center from the United Kingdom.

Participant flow — Overall Study
MilestoneParacetamol and CaffeineParacetamolPlacebo
Started678
Completed666
Not completed012
Withdrew: Other (not specified)012

Outcome measures

PrimaryChange From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2)

Error adjusted SRT was one of the main outcomes of the Axon Sports Priming Application. The Axon Sports Priming Application is a computerized test performed on a tablet device that measures cognitive performance, namely psychomotor speed. Axon sports test assessment included 1. Pain-state assessment performed at Visit 2 (Day 2 pre-treatment assessment and post-treatment assessment 1hour \[hr\] ± 15 minutes \[mins\] post-dosing) and 2. Pain-free assessment performed at Visit 3 (Day 3).

Time frame:
At Day 2 (pre and post-treatment) and Day 3 of the study
Reported as:
Median · milliseconds (msec)
Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2)
milliseconds (msec)Paracetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment0.05 (0.0 to 0.2)0.07 (0.0 to 0.8)0.06 (0.0 to 0.2)
Change from pain-free state at Day2 post-treatment0.04 (0.0 to 0.4)0.01 (0.0 to 0.3)0.00 (-0.2 to 0.1)
PrimaryChange From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2)

The reaction time of five-choice reaction time task (provided by Cambridge Cognition) was measured. In five-choice reaction time task, all the participants hold down a button at the bottom of the screen till a yellow spot appears in one of the five circles at the top of the screen. Participants then released the button and touch inside of the circle where the yellow spot appeared as quickly as they can. The median duration, between the onset of the stimulus and the release of the button, was recorded as reaction time. Calculated for correct, assessed trials where the stimulus appeared in any one of five locations.

Time frame:
At Day 2 (pre and post-treatment) and Day 3 of the study
Reported as:
Median · msec
Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2)
msecParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment2.00 (-17.5 to 36.0)-1.75 (-41.0 to 170.5)-1.00 (-6.5 to 18.5)
Change from pain-free state at Day2 post-treatment25.75 (-11.5 to 83.5)12.50 (-65.5 to 26.0)-8.00 (-28.0 to 24.5)
PrimaryChange From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2)

OTS was a measure of executive function and takes approximately 10 minutes to complete. The participant was shown two displays containing three coloured balls. The displays were presented in such a way that they can easily be perceived as stacks of coloured balls held in stockings or socks suspended from a beam. There was a row of numbered boxes along the bottom of the screen. The test administrator first demonstrated to the participant how to use the balls in the lower display to copy the pattern in the upper display, and completed one demonstration problem, where the solution requires one move. The participant then completed three further problems, one each of two moves, three moves, and four moves. Next, the participant was shown further problems, and participants worked out in their head how many moves the solutions to these problems required, and then touch the appropriate box at the bottom of the screen to indicate their response.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Mean · OTS of correct first box choice
Change From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2)
OTS of correct first box choiceParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-2.67 ± 3.0770.00 ± 1.095-0.20 ± 1.789
Change from pain-free state at Day2 post-treatment-1.83 ± 1.9412.17 ± 1.835-1.40 ± 2.702
PrimaryChange From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2)

AST was a measure of executive attention. The test displayed an arrow which can appear on either side of the screen and can point in either direction. Each trial displayed a cue at the top of the screen that indicates whether to press the right or left button. Some trials displayed congruent stimuli (e.g. arrow on the right side of the screen pointing to the right) whereas other trials display incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side of the screen pointing to the left). The AST congruency cost was the difference between the median latencies of response (from stimulus appearance to button press) on the trials that were congruent versus the trials that were incongruent. It was calculated by subtracting the median of congruent from incongruent latency. A positive score indicated response was faster on congruent trials and a negative score indicated response was faster on incongruent trials.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Median · msec
Change From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2)
msecParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-3.25 (-44.5 to 46.5)46.25 (-22.5 to 99.5)2.50 (-4.0 to 113.5)
Change from pain-free state at Day2 post-treatment-8.25 (-44.0 to 43.5)23.00 (-5.0 to 104.0)22.50 (-171.5 to 113.5)
PrimaryChange From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2)

SWM task was a measure of working memory. The task involved number of coloured squares (boxes) being shown on the screen. The aim of this test was to find one blue token in the boxes shown to the participants by process of elimination and used these to fill up an empty column on the right-hand side of the screen. The number of boxes gradually increased up to a maximum of eight boxes to search and the colour and position of the boxes changed from trial to trial. SWM between errors was defined as times the participant revisited a box in which a token has previously been found. This was calculated for trials of four, six and eight tokens.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Mean · SWM between errors
Change From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2)
SWM between errorsParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-9.33 ± 18.74725.17 ± 29.07513.80 ± 23.994
Change from pain-free state at Day2 post-treatment4.83 ± 22.24813.50 ± 23.193-9.80 ± 32.920
PrimaryChange From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2)

RVP task was measures of attention. A white box appeared in the centre of the computer screen, inside which digits, from 2 to 9, appeared in a pseudo-random order, at the rate of 100 digits per minute. Participants were requested to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register responses using the press pad. The RVPA (A prime) was the signal detection measure of sensitivity to the target, regardless of response tendency (the expected range will be 0.00 to 1.00; bad to good). RVP metric was a measure of how good the subject was at detecting target sequences.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Median · msec
Change From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2)
msecParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-0.04 (-0.1 to 0.0)0.00 (0.0 to 0.0)-0.03 (-0.1 to 0.0)
Change from pain-free state at Day2 post-treatment-0.02 (-0.1 to 0.0)-0.01 (-0.1 to 0.0)0.00 (0.0 to 0.0)
SecondaryChange From Pain-free State (Day 3) in Grip Force in Pain State (Day 2)

This task was a measure of grip strength. The participant held the dynamometer in their dominant hand and the arm was swung from above the head to by the side of the body. If the dominant arm or hand was painful then the non-dominant hand was used. The participant was instructed to assert maximum effort during the squeezing motion and maintain it for about 4 seconds using a metronome. Participant conducted the movement 4-times (1 practice effort and 3 test efforts) and there was a 1-minute recovery period between each effort.

Time frame:
At Day 2 (pre and post-treatment) and Day 3 of the study
Reported as:
Mean · Kilogram (Kg)
Change From Pain-free State (Day 3) in Grip Force in Pain State (Day 2)
Kilogram (Kg)Paracetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-1.98 ± 5.505-3.87 ± 3.792-1.70 ± 3.533
Change from pain-free state at Day2 post-treatment0.68 ± 2.384-2.80 ± 3.059-0.46 ± 1.365
SecondaryChange From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2)

Time to standing provides a simple assessment of physical mobility. From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Time to standing recorded which was measured using a stopwatch. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Median · Seconds
Change From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2)
SecondsParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment0.10 (-0.4 to 0.2)0.13 (-0.2 to 0.3)0.09 (0.0 to 0.3)
Change from pain-free state at Day2 post-treatment-0.01 (-0.2 to 0.5)-0.08 (-0.3 to 0.4)0.04 (-0.2 to 0.6)
SecondaryChange From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2)

From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort. GRF was measured during the movement analyzed using a force plate interfaced with a computer.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Mean · Newtons
Change From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2)
NewtonsParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment3.35 ± 11.781-19.80 ± 43.7883.75 ± 11.214
Change from pain-free state at Day2 post-treatment4.21 ± 8.295-13.85 ± 47.3873.08 ± 12.064
SecondaryChange From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2)

Participants performed a walking assessment in comfortable walking shoes to measure gait parameter contact phase. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Median · Seconds
Change From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2)
SecondsParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment0.03 (0.0 to 0.1)0.03 (0.0 to 0.1)0.00 (0.0 to 0.0)
Change from pain-free state at Day2 post-treatment0.03 (-0.0 to 0.1)0.02 (-0.0 to 0.1)0.01 (-0.02 to 0.03)
SecondaryChange From Pain-free State (Day 3) in Stride Length in Pain State (Day 2)

Participants performed a walking assessment in comfortable walking shoes to measure gait parameter stride length. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

Time frame:
At Day 2 (pre and post treatment) and Day 3 of the study
Reported as:
Mean · Centimeter
Change From Pain-free State (Day 3) in Stride Length in Pain State (Day 2)
CentimeterParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-0.06 ± 0.098-0.08 ± 0.123-0.02 ± 0.038
Change from pain-free state at Day2 post-treatment-0.04 ± 0.084-0.06 ± 0.116-0.04 ± 0.037
SecondaryChange From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2)

Participants performed a walking assessment in comfortable walking shoes to measure gait parameter walking speed over 5-10m for each foot. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.

Time frame:
At Day 2 (pre and post-treatment) and Day 3
Reported as:
Mean · meters/second
Change From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2)
meters/secondParacetamol and CaffeineParacetamolPlacebo
Change from pain-free state at Day 2 pre-treatment-0.11 ± 0.112-0.10 ± 0.180-0.02 ± 0.052
Change from pain-free state at Day2 post-treatment-0.10 ± 0.105-0.07 ± 0.157-0.03 ± 0.043

Adverse events

Collected over Up to 61 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol and Caffeine0/6 (0%)0/6 (0%)0/6 (0%)
Paracetamol0/7 (0%)0/7 (0%)1/7 (14.3%)
Placebo0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventParacetamol and CaffeineParacetamolPlacebo
Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders0/61/70/8
Gastrooesophageal reflux diseaseGastrointestinal disorders0/60/71/8
HypercholesterolaemiaMetabolism and nutrition disorders0/60/71/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Paracetamol and CaffeineParacetamolPlaceboTotal
Mean27.8 ± 4.8330.0 ± 9.4540.0 ± 15.8733.2 ± 12.31
Sex: Female, Male
Sex: Female, Male(Participants)Paracetamol and CaffeineParacetamolPlaceboTotal
Female45514
Male2237
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paracetamol and CaffeineParacetamolPlaceboTotal
American Indian or Alaska Native0000
Asian2215
Native Hawaiian or Other Pacific Islander0000
Black or African American1023
White35412
More than one race0011
Unknown or Not Reported0000
08

Study locations

1 site
  • GSK Investigational Site
    Brentford, Middlesex TW8 9DA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Feb 2017, 3 months.

Results were first posted in Aug 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2016
First posted
Nov 28, 2016
StartActual
Oct 31, 2016
Primary completionActual
Feb 6, 2017
CompletionActual
Feb 6, 2017
Results first posted
Aug 28, 2018
Last update
Aug 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02974114
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 28, 2016
Start date
Oct 31, 2016
Primary completion
Feb 6, 2017
Completion
Feb 6, 2017
Results posted
Aug 28, 2018
Last update
Aug 28, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Caffeine

Start the discussion